Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,364 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Syringe Clear all
Completed Phase 3 Interventional Results available

Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

NCT02652767
View directory record Official record
Conditions
Optic, Atrophy, Hereditary, Leber
Interventions
GS010, Sham Intravitreal Injection
Biological · Device
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 30, 2026, 10:37 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Canakinumab in Patients With Myelofibrosis

NCT05467800
View directory record Official record
Conditions
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF, Post-polycythemia Vera Related Myelofibrosis, PV-MF
Interventions
Canakinumab
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Tampa, Florida • Westwood, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Not applicable Interventional

Effect of Agave Syrup, Placebo, and No Treatment on Nocturnal Cough and Sleep Quality for Coughing Infants/Toddlers and Their Parents

NCT01721395
View directory record Official record
Conditions
Cough
Interventions
Agave Syrup
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
2 Months to 48 Months
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Oct 30, 2026, 10:37 AM EDT
Enrolling by invitation Phase 3 Interventional

A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT07793409
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Lunsekimig
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Newport Beach, California • Boynton Beach, Florida • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

NCT04102007
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • North Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 1 Interventional

Study of KCC Peptide Application in the Colon

NCT02156557
View directory record Official record
Conditions
Colon Polyps, Colorectal Cancer, Inflammatory Bowel Disease (IBD)
Interventions
Colon KCC Heptapeptide
Biological
Lead sponsor
Danielle Kim Turgeon
Other
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

NCT04435366
View directory record Official record
Conditions
Geographic Atrophy, Macular Degeneration
Interventions
Avacincaptad Pegol, Sham
Drug
Lead sponsor
IVERIC bio, Inc.
Industry
Eligibility
50 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
96
States / cities
Beverly Hills, California • Campbell, California • Fresno, California + 86 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

NCT04432831
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Faricimab, Sham Procedure
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
119
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 30, 2026, 10:37 AM EDT
Terminated Phase 2 Interventional Results available

Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma

NCT01207765
View directory record Official record
Conditions
Multiple Myeloma
Interventions
indium-111-ibritumomab tiuxetan, 90Y Zevalin
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug

NCT03014674
View directory record Official record
Conditions
Asthma
Interventions
Lyophilized mepolizumab, Liquid mepolizumab, Prefilled autoinjector, Prefilled Safety Syringe
Biological · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 30, 2026, 10:37 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

RCT Comparing ESWT With PRP for Plantar Fasciitis in High Demand Cohort

NCT02668510
View directory record Official record
Conditions
Fasciitis, Plantar
Interventions
platelet rich plasma, Normal saline
Biological · Drug
Lead sponsor
Edna Rath
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of Tebipenem (SPR994) Crushed Tablet

NCT05296382
View directory record Official record
Conditions
Relative Bioavailability
Interventions
Tebipenem tablet form, Tube feeds
Drug · Other
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects

NCT02675023
View directory record Official record
Conditions
Healthy
Interventions
M923
Biological
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
603 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 2 Interventional Results available

Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine

NCT04192370
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Cannabidiol 600mg
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 30, 2026, 10:37 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

NCT00865566
View directory record Official record
Conditions
HIV Infections
Interventions
DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine, DNA vaccine placebo, HIV-1 recombinant adenovirus vaccine placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
2,504 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis

NCT04729621
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
TVB-009, Prolia®
Combination Product
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 3 Interventional

Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin

NCT00329628
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (BAY59-7939), Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 30, 2026, 10:37 AM EDT
Completed No phase listed Observational Results available

DyeVert™ Plus Contrast Reduction System Multicenter Observational Study

NCT03715452
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
DyeVert Plus Contrast Reduction System
Device
Lead sponsor
Osprey Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Torrance, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 3 Interventional

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

NCT06077864
View directory record Official record
Conditions
Obesity
Interventions
survodutide, Placebo
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
5,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
153
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 135 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Not applicable Interventional

Self-injection and Self-management

NCT02417493
View directory record Official record
Conditions
Food Allergy
Interventions
Simulation of epinephrine self-injection
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
13 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 2 Interventional Results available

Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB

NCT02748317
View directory record Official record
Conditions
Lower Urinary Tract Symptoms
Interventions
Lactobacillus rhamnosus GG
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 30, 2026, 10:37 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Therapeutic Epidural Patch Versus Pain Block in the Midface for Headache

NCT03112720
View directory record Official record
Conditions
Postdural Puncture Headache
Interventions
Epidural Blood Patch, Sphenopalatine Ganglion Block
Device · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
13 Years to 92 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

BCG Vaccine for Health Care Workers as Defense Against COVID 19

NCT04348370
View directory record Official record
Conditions
Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere
Interventions
BCG Vaccine, Placebo Vaccine
Biological
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 75 Years
Enrollment
659 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Bryan, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 30, 2026, 10:37 AM EDT